Induction of tumor-specific cytotoxic T cells after intratumoral administration of AdmCD40L-modified DCs.
(A,B) CT26 tumors. DCs purified from bone marrow were transduced in vitro with AdmCD40L (▪) or AdNull (□) at moi of 40 for 24 hours, and 2 × 105-modified DCs were administered intratumorally to day 8 established CT26 tumors in Balb/c mice. Controls included tumor-bearing mice without any treatment (Δ). Ten days after treatment, splenocytes were isolated and restimulated in vitro for 5 days with mitomycin C-treated CT26 cells and assayed for cytolytic function against 51Cr-labeled CT26 targets (panel A) or SVBalb targets (panel B). (C,D) B16 tumors. The study was identical to that described in panel A, except for the different tumor type. Ten days after administration of transduced DCs, the splenocytes were isolated, restimulated with mitomycin C-treated B16 cells, and assayed as in A,B. Shown are data for 51Cr-labeled B16 targets (panel C) and C3 targets (panel D). All panels, results are presented as the mean ± standard error (n = 3/data point).
